Nemluvio (nemolizumab-ilto) — Prior Authorization Criteria for Atopic Dermatitis and Prurigo Nodularis
Customize your policy alerts
Sign up for all West Virginia Bureau for Medical Services (Department of Human Services) policy alerts
Know when West Virginia Bureau for Medical Services (Department of Human Services) releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization criteria and reauthorization requirements for Nemluvio (nemolizumab-ilto) for treatment of moderate-to-severe atopic dermatitis in patients ≥12 years and prurigo nodularis in adults ≥18 years under West Virginia Bureau for Medical Services.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Therapy (Atopic Dermatitis)
Covered when ALL of the following are met for AD
Trial of medium-to-high potency corticosteroid is required unless affected area involves sensitive areas (face, skin folds, genitals); if sensitive, two other agents from the list are required prior to approval.
Reauthorization (Atopic Dermatitis)
Covered when ALL of the following are met for AD reauthorization
Initial authorization may be for 6 months; continuation may be granted for up to 12 months.
Initial Therapy (Prurigo Nodularis)
Covered when ALL of the following are met for PN
PN must be chronic pruritus not caused by another active condition.
Reauthorization (Prurigo Nodularis)
Covered when ALL of the following are met for PN reauthorization
Initial authorization may be for 6 months; continuation may be granted for up to 12 months.
For Prurigo Nodularis (PN), therapy with Nemluvio is limited to patients with documented moderate-to-severe PN lasting at least three months where pruritus is not secondary to another active cause (for example, neuropathic or psychogenic pruritus is excluded). Approval requires documentation that the nodular disease is clinically significant: ≥20 nodular lesions distributed bilaterally on the legs, and/or both arms, and/or trunk with an average itch severity of PP‑NRS ≥7.
Prescriptions must be made by, or in consultation with, an MD/DO dermatologist, allergist, or immunologist, and the patient must meet the FDA age indication (see coverage criteria). Prior to approval, the record must show a documented intolerance, allergy, or treatment failure after a 90‑day trial with Dupixent, and an inadequate response to a super‑potent topical corticosteroid or intralesional corticosteroid. These requirements reflect the policy’s exclusion of PN that is caused by another active pruritic condition and establish the specific nodularity and severity thresholds needed for coverage.
Key Measures & Coding Thresholds
Definitions
Provider Actions, Documentation & Step Therapy
Prior authorization required; prescriber or documented consultation required
Prior authorization is required for Nemluvio. The request must show the drug is prescribed by, or in consultation with, an M.D./D.O. allergist, immunologist, or dermatologist and include evidence that the patient meets the listed clinical criteria for the requested indication.
- Prescriber must be an M.D./D.O. allergist, immunologist, or dermatologist, or documentation of consultation with one.
- Include evidence the patient meets all clinical criteria for the requested indication (AD or PN).
Step therapy: required topical and biologic trials before approval
Document trials of required topical therapies and prior biologics before approval: for AD, two distinct 30-day trials from the specified list within the past 12 months and a 90-day trial of Adbry and Dupixent; for PN, a 90-day trial of Dupixent and an inadequate-response trial to a super‑potent topical corticosteroid or intralesional corticosteroid.
- AD: Two separate >=30-day trials in last 12 months of (a) medium‑to‑high potency topical corticosteroid* OR (b) Elidel OR (c) Eucrisa OR (d) tacrolimus. *If affected area is sensitive, trial of medium‑to‑high potency corticosteroid may be omitted but two other agents are still required.
- AD: Documented intolerance, allergy, or treatment failure after a 90‑day trial with Adbry and Dupixent.
- PN: Documented intolerance, allergy, or treatment failure after a 90‑day trial with Dupixent.
- PN: Trial with inadequate response/treatment failure to a super‑potent topical corticosteroid or intralesional corticosteroid.
Required documentation for AD: diagnosis, scores, areas, and BSA
Submit documentation showing AD diagnosis, objective severity measures, affected areas, and body surface area involvement (BSA >= 10%).
- Diagnosis of moderate‑to‑severe atopic dermatitis.
- PP‑NRS score >= 7 and/or EASI score >= 16.
- Documentation of areas of involvement and symptom severity.
- Affected BSA reported and >= 10%.
Required documentation for PN: duration, nodules, PP‑NRS, exclusion of other causes
Provide documentation supporting the diagnosis of prurigo nodularis including duration, lesion counts/distribution, itch severity, and exclusion of other causes of pruritus.
- Duration of PN >= 3 months and that pruritus is not caused by another active condition (e.g., neuropathic or psychogenic pruritus).
- Count and distribution showing >= 20 nodular lesions distributed bilaterally on legs and/or both arms and/or trunk.
- Average PP‑NRS (itch) score >= 7.
- Documentation of intolerance, allergy, or treatment failure after a 90‑day trial with Dupixent and inadequate response to super‑potent topical or intralesional corticosteroid.
Denial risk for AD: missing severity, BSA, prescriber, or prior therapy evidence
Denial may occur if AD requests lack required objective severity measures, prescriber/consultation documentation, BSA threshold, or evidence of required prior topical and biologic therapy trials.
- Missing PP‑NRS >= 7 or EASI >= 16.
- BSA not documented as >= 10%.
- No documentation that prescriber is an M.D./D.O. allergist, immunologist, or dermatologist or that a consultation occurred.
- Lack of two distinct >=30‑day topical therapy trials in past 12 months or missing documented 90‑day trials/intolerance for Adbry and Dupixent.
Denial risk for PN: missing lesion counts, PP‑NRS, exclusion of causes, or prior therapy
Denial may occur for PN requests that do not document required lesion counts/distribution, PP‑NRS severity, exclusion of other causes, or required prior biologic/topical/intralesional therapy trials.
- Absence of documentation showing >= 20 nodular lesions distributed bilaterally as specified.
- Missing average PP‑NRS itch score >= 7.
- Failure to document PN duration >= 3 months or exclusion of other active causes of pruritus.
- No documented 90‑day Dupixent trial or no trial/inadequate response to a super‑potent topical corticosteroid or intralesional corticosteroid.
Background
Nemluvio (nemolizumab‑ilto) is indicated under the PN criteria as a targeted therapy for patients with moderate‑to‑severe prurigo nodularis. For PN coverage the policy requires objective baseline measures and prior therapy trials: the diagnosis must be confirmed by a treating specialist (MD/DO dermatologist, allergist, or immunologist), the condition must be chronic (≥3 months), and disease severity is defined by both lesion count and itch intensity (≥20 nodular lesions plus PP‑NRS ≥7). The policy also mandates documented failure, intolerance, or allergy to a 90‑day trial of Dupixent and an inadequate response to a super‑potent topical or intralesional corticosteroid before Nemluvio will be authorized.
Revision History
Policy effective date for Nemluvio (nemolizumab-ilto) prior authorization criteria was established.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.